On Wednesday, Bengaluru based Zydus Cadila said that its developed potential COVID-19 vaccine, ‘ZyCoV-D’ has been found safe to use and well-tolerated in an early-stage human trial.
An independent data safety monitoring board has concluded that the vaccine is safe to use, based on health analysis of an early-stage vaccine trial participants who were provided doses beginning from July 15.
The company will now commence its mid-stage trial of the vaccine, from Thursday onwards, with 1,000 healthy adult participants to test the effectiveness of the vaccine. If the trails are successful and the government approves, the company is likely to manufacture around 100 million doses a year.
Last month, chairman of Zydus Cadila said, “Zydus plans to complete late-stage trials for ZyCoV-D by February or March and could produce up to 100 million doses a year initially”.